中国比较医学杂志2017，Vol.27Issue(3)：25-30,6.DOI:10.3969.j.issn.1671-7856.2017.03.005
利用实时细胞分析技术检测胰腺癌细胞的药物敏感性
Drug sensitivity assessment of pancreatic cancer cells by real-time cell analysis
摘要
Abstract
Objective To assess the drug sensitivity of pancreatic cancer cells based on real-time cell analysis and provide a reference for individualized diagnosis and treatment of pancreatic cancer.Methods Three human pancreatic cancer cells lines SW1900, Capan-2 and PANC-1 were selected and treated with gemcitabine hydrochloride and tegafur gimeracil oteracil potassium capsules, respectively.After 24 hours of culture, the cells were treated with the two drugs in gradient concentration.The cell growth curves before and after the drug administration was monitored using a real-time cells analyzer and the growth inhibition rates (IC50) of the drugs of the pancreatic cancer cells were calculated.At the same time, the cells in the cell culture plate were treated with the drug, and acridine orange/ethidium bromide (AO/EB) staining and laser scanning confocal microscopy were performed to observe the changes of cells after the drug administration.Results 72 hours after the drug administration, IC50 values for the three cell lines were different.The IC50 values of gemcitabine hydrochloride for SW1900, Capan-2 and PANC-1 cells were 1.69 μmol/L, 10.05 μmol/L and 12.74 μmol/L, respectively.The IC50 values of tegafur capsule for SW1900, Capan-2 and PANC-1 cells were 180.29 μmol/L, 765.70 μmol/L and 95.57μmol/L, respectively.AO/EB staining confirmed the reliability of IC50.Conclusions SW1900 and Capan-2 cells can be used as the control for gemcitabine hydrochloride and tegafur gimeracil oteracil potassium capsules to establish cell models for drug screening in vitro, which provides a reference for the application of the technology in anticancer drugs screening.关键词
胰腺癌/化疗药物/实时细胞分析/药物敏感性Key words
Pancreatic cancer/Chemotherapeutic drugs/Real-time cell analysis/Drug sensitivity分类
医药卫生引用本文复制引用
靳亚西,孙彩显,高虹,张连峰,张丽..利用实时细胞分析技术检测胰腺癌细胞的药物敏感性[J].中国比较医学杂志,2017,27(3):25-30,6.基金项目
卫生行业科研专项 (201402001). （201402001）
